LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

PRIMED 2nd General Assembly

24/07/2024

PRESS RELEASE

Brussels, 19th June 2024

The PRIMED consortium held its 2nd General Assembly (GA) online, six months after the project’s Kick-off Meeting (KoM). This milestone event showcased significant progress in PRIMED’s mission to redesign the primary sector for enhanced bioeconomy development across Europe. The project focuses on integrating primary producers into innovative value chains, promoting sustainable rural economies through a collaborative multi-actor approach.

The assembly focused on two key areas: Circular Business Models in Bioeconomy (CBMB) and Living Labs.

CBMBs represent innovative forms of cooperation that integrate primary producers into new bioeconomy value chains. These models address critical challenges such as fragmented knowledge sharing, complex supply chains, and the need for new logistical networks.

PRIMED Living Labs, established in Spain, Portugal, Italy, Ireland, and Finland, serve as real-world environments where these models are demonstrated and tested. Detailed factsheets have been prepared for each lab, enabling ongoing critical analysis and identification of political, technical and economic barriers. The project is actively engaged in discussions on methodologies, transformations, and processes to be applied in new business cases, along with assessing associated risks and benefits. A key focus of these Living Labs is the validation of high-value bio-based products developed for end-use applications.

Key achievements reported at the assembly include:

  • Advanced development of the Open Access Toolbox: This digital platform, designed to facilitate collaboration among stakeholders, will include the Business Model Navigator, Business Cases, Governance Models, and Shared Agendas developed during the PRIMED project. Currently, the design of the Toolbox is at an advanced stage.
  • Progress in CBMB: Analysis is underway for the five value chains associated with the Living Labs, focusing on new bio-based products, processes, and integrated services to identify their value generation architecture, value capture sources, and key challenges. Additionally, a policy analysis, governance analysis, investment options, and indicators and impact monitoring methodology for each CBMB developed for the Living Labs are being carried out.
  • Launch of the 1st Open Call for end-users: In support of the Living Labs’ objectives, guidelines and selection criteria have been published to validate high-value bio-based products in end-use applications. End-user selections will be announced in November.
  • Enhanced project visibility: The PRIMED website and social media channels are now live, with a comprehensive video overview of the project planned for early 2025.
  • The 2ndGA concluded with a comprehensive review of the progress made and the challenges ahead. This session outlined the successful developments in CBMB and set forth the short-term goals to be achieved. Key next steps include further refinement of methodologies for stakeholder engagement, the initiation of defining Key Performance Indicators (KPIs) to calculate the impact of CBMBs, and the continued promotion and execution of the Open Call, to secure at least one end-user for each Living Lab and ensure success.
  • The PRIMED project, funded by the European Commission’s Horizon Europe program, brings together 13 partners from 7 European countries. The consortium includes business modelexperts from RUB – Ruhr-Universität Bochum, biological and chemical researchers, Living Labs (Alcarràs Bioproductors, CeNTI – Centro de Nanotecnologia e Materiais Técnicos, Funcionais e Inteligentes, FILSE – Finanziaria Ligure per lo Sviluppo Economico, IBF – Irish Bioeconomy Foundation and VTT – Technical Research Centre of Finland), policy experts (the European Association for Bioindustries), governance and social impact researchers (LUT University), biomass and techno-economic experts (SINTEF), and consultants in agri-food, agriculture, and sustainability (AKIS Research, BioHubCat and INVENIAM Group, and NAKED Innovations). The next General Assembly is scheduled for December 2024 in Catalonia, Spain.

 

Authors: Mario González

PRIMED 2nd General Assembly


Download

Share
Francesca Degli Agostini
Francesca Degli Agostini

Related posts

03/07/2025

Life Sciences Strategy Embraces Biotech for Global Impact


Read more
26/06/2025

EuropaBio AGM 2025: Association Chair, Executive Committee and Board announced


Read more
26/06/2025

Health Biomanufacturing: Feedstock for Preparedness and Resilience


Read more

Important links

  • EuropaBio Position on the Critical Medicines Act
  • Life Sciences Strategy Embraces Biotech for Global Impact

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.